As we transform drug development in the age of A.I., fine-tuning our patient understanding will be more important than ever. When it comes to R&D, the challenge before us is to become experts at measuring disease—and disease progression—in order to treat it. A discussion with one of the leading minds in R&D on this new imperative.
Dr. Hal Barron, Chief Scientific Officer and President, Research & Development, GSK
mmelvin 
